A Bioequivalence Study of Two Different Dosage Form of Genakumab

Inclusion Criteria: * Healthy male aged ≥18 years old and≤45 years old; * The Body mass index (BMI): 19-26 kg/m2 (inclusive), and body weight ≥50 kg; * Subjects who voluntarily signed the informed consent form (ICF)； * Subjects of childbearing potential had no plans for pregnancy or donating sperm/ova and agreed to use reliable contraception during the study and for 3 months after the last dose; Exclusion Criteria: * (During screening) Allergic to the investigational product, any of its components, or any biological agents, or had a history of multiple allergies (two or more) to drugs, foods, or environmental factors, or were prone to allergic symptoms such as rashes or urticaria; * (During screening inquiry) Previously unable to tolerate intravenous puncture/indwelling needles for blood collection, or had a history of hemophobia or fear of needles; * Abnormal vital signs (pulse \< 50 bpm or \> 100 bpm when awake, systolic blood pressure ≥ 140 mmHg or \< 90 mmHg or diastolic blood pressure ≥ 90 mmHg or \< 60 mmHg, forehead temperature \> 37.3°C); ECG QTc-F interval ≥ 460 ms, or other clinically significant ECG abnormalities; abnormal findings in physical examination, laboratory tests, chest CT, and abdominal B-mode ultrasound; * Subjects who have positive results of human immunodeficiency virus antibodies (HIV-Ab), or hepatitis B surface antigen (HBsAg), or hepatitis C virus antibodies (HCV-Ab), or syphilis specific antibodies (TPPA)； * (During screening/admission inquiry)…